|1.||Le Foll, Bernard: 4 articles (01/2016 - 03/2013)|
|2.||Brady, Kathleen T: 4 articles (11/2015 - 09/2006)|
|3.||Fava, Maurizio: 4 articles (09/2015 - 03/2006)|
|4.||Nierenberg, Andrew A: 4 articles (12/2012 - 03/2006)|
|5.||McRae-Clark, Aimee L: 3 articles (11/2015 - 11/2009)|
|6.||Kline, Anthony E: 3 articles (12/2014 - 07/2012)|
|7.||Cheng, Jeffrey P: 3 articles (12/2014 - 07/2012)|
|8.||Sessler, Daniel I: 3 articles (07/2009 - 01/2004)|
|9.||Boileau, Isabelle: 2 articles (01/2016 - 03/2013)|
|10.||Baker, Nathaniel L: 2 articles (11/2015 - 10/2015)|
|1.||Anxiety Disorders (Anxiety Disorder)
01/01/1997 - "Buspirone is a nonbenzodiazepine anxiolytic that has been effective in uncontrolled trials for treating childhood anxiety disorders. "
05/01/1996 - "Buspirone is effective for the treatment of anxiety disorders in children. "
07/01/1996 - "This study was designed to evaluate the anxiolytic efficacy of buspirone in patients with a diagnosis of generalized anxiety disorder (GAD) with coexisting mild depressive symptoms. "
01/01/1999 - "Buspirone is an azapirone with 5-HT1A partial agonist activity which has demonstrated efficacy in the treatment of generalized anxiety disorder, commonly referred to as persistent anxiety. "
07/01/1996 - "Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms."
|2.||Panic Disorder (Panic Attack)
02/01/1990 - "Is buspirone effective for panic disorder?"
09/01/1990 - "Studies conducted with patients suffering from panic disorder have so far been inconclusive, and thus buspirone is, for the present at least, not recommended for routine treatment of panic disorder. "
02/24/1990 - "Buspirone metabolite and panic attacks."
02/01/1990 - "Buspirone was not significantly superior to placebo in its antipanic or anxiolytic effects in panic disorder patients."
08/01/1988 - "Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate."
|3.||Phobic Disorders (Phobia)
04/01/1997 - "The results of open pilot studies suggest that the serotonin-1A (5-HT1A) receptor agonist buspirone might be effective in social phobia. "
04/01/1997 - "In the present study, the efficacy of buspirone was investigated in patients with social phobia using a 12-week double-blind placebo-controlled design. "
04/01/1997 - "The results of the study do not support the results of open studies, in which a reduction of social anxiety and social avoidance was reported in patients with social phobia treated with buspirone."
04/01/1997 - "Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study."
08/01/1993 - "The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required."
|4.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
12/01/1998 - "The most recent studies have been unable to demonstrate the efficacy of buspirone in smoking cessation or in the relief of withdrawal symptoms. "
05/01/2003 - "It is concluded that buspirone was effective in attenuating the objective and subjective withdrawal symptoms that follow opiate use cessation."
02/01/1992 - "In a double-blind, randomized, placebo-controlled trial, we determined the effects of buspirone on the withdrawal symptoms associated with smoking cessation in 40 long-term cigarette smokers. "
01/01/1992 - "Buspirone effect on tobacco withdrawal symptoms: a randomized placebo-controlled trial."
01/01/1991 - "This paper reports on a double blind trial of the effect of buspirone, 15 mg per day, on cigarette withdrawal symptoms and ability of smokers to maintain abstinence during treatment. "
|5.||Major Depressive Disorder (Major Depressive Disorders)
01/01/1986 - "Open trial of buspirone in the treatment of major depressive disorder."
04/01/1994 - "We administered the serotonin-1a agonist buspirone (0.4 mg/kg orally) as a neuroendocrine challenge agent to a group of male patients with DSM-III-R major depressive disorder (MDD) (n = 13) and a group of male healthy controls (n = 10). "
01/01/2015 - "In this review presents the results of clinical trials of buspirone as an adjunctive therapy in cases with previous ineffective use of antidepressants in patients with major depressive disorder."
12/01/2012 - "Based on these data, we conducted an exploratory 6-week, multi-center, double-blind, randomized, placebo- and comparator-controlled study of the combination of buspirone and melatonin in subjects with acute Major Depressive Disorder (MDD). "
12/01/2012 - "An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery."
|2.||Serotonin 5-HT1 Receptor Agonists
|3.||Antidepressive Agents (Antidepressants)
|4.||Serotonin (5 Hydroxytryptamine)
|6.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
|1.||Drug Therapy (Chemotherapy)
|4.||Self Administration (Administration, Self)